| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Flow Cytometry | 39 | 2024 | 1162 | 6.950 |
Why?
|
| Single-Cell Analysis | 16 | 2025 | 362 | 4.180 |
Why?
|
| Germinal Center | 6 | 2022 | 64 | 1.880 |
Why?
|
| Signal Transduction | 24 | 2025 | 5216 | 1.560 |
Why?
|
| Glioblastoma | 3 | 2023 | 353 | 1.470 |
Why?
|
| Neoplasms | 11 | 2022 | 2906 | 1.440 |
Why?
|
| Unsupervised Machine Learning | 2 | 2021 | 23 | 1.310 |
Why?
|
| B-Lymphocytes | 6 | 2022 | 870 | 1.280 |
Why?
|
| Myeloid-Derived Suppressor Cells | 4 | 2021 | 76 | 1.280 |
Why?
|
| Melanoma | 5 | 2022 | 759 | 1.240 |
Why?
|
| Leukemia, Myeloid, Acute | 7 | 2023 | 686 | 1.230 |
Why?
|
| Lymphoma, Follicular | 8 | 2017 | 56 | 1.200 |
Why?
|
| Monocytes | 5 | 2022 | 539 | 1.160 |
Why?
|
| Immunophenotyping | 10 | 2024 | 319 | 1.140 |
Why?
|
| Monitoring, Immunologic | 2 | 2018 | 25 | 1.050 |
Why?
|
| Mass Spectrometry | 5 | 2019 | 730 | 1.040 |
Why?
|
| Receptors, Antigen, B-Cell | 6 | 2022 | 130 | 0.940 |
Why?
|
| Image Cytometry | 3 | 2022 | 11 | 0.940 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2021 | 193 | 0.900 |
Why?
|
| Benzofurans | 1 | 2025 | 26 | 0.900 |
Why?
|
| Biological Products | 3 | 2025 | 257 | 0.880 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2017 | 85 | 0.860 |
Why?
|
| Dendritic Cells | 2 | 2019 | 499 | 0.830 |
Why?
|
| Otolaryngology | 2 | 2017 | 108 | 0.820 |
Why?
|
| Macrophages | 3 | 2023 | 1507 | 0.750 |
Why?
|
| Machine Learning | 3 | 2018 | 587 | 0.740 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2022 | 574 | 0.680 |
Why?
|
| Humans | 98 | 2026 | 145474 | 0.670 |
Why?
|
| Phagocytes | 2 | 2019 | 80 | 0.670 |
Why?
|
| Picornaviridae Infections | 1 | 2021 | 53 | 0.660 |
Why?
|
| Brain Neoplasms | 2 | 2023 | 1329 | 0.650 |
Why?
|
| Proteomics | 4 | 2022 | 1188 | 0.630 |
Why?
|
| CD40 Antigens | 2 | 2019 | 90 | 0.630 |
Why?
|
| Fluorescent Dyes | 3 | 2021 | 333 | 0.620 |
Why?
|
| Immunologic Memory | 3 | 2021 | 368 | 0.620 |
Why?
|
| Cells | 1 | 2020 | 25 | 0.620 |
Why?
|
| Education | 1 | 2020 | 104 | 0.600 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2018 | 223 | 0.600 |
Why?
|
| Algorithms | 6 | 2021 | 1845 | 0.600 |
Why?
|
| Phosphorylation | 11 | 2022 | 1707 | 0.590 |
Why?
|
| Computational Biology | 4 | 2017 | 669 | 0.580 |
Why?
|
| Tumor Microenvironment | 8 | 2023 | 734 | 0.580 |
Why?
|
| CD40 Ligand | 1 | 2019 | 40 | 0.580 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2023 | 165 | 0.570 |
Why?
|
| Nestin | 1 | 2018 | 19 | 0.560 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 126 | 0.540 |
Why?
|
| Mouth Neoplasms | 3 | 2026 | 90 | 0.530 |
Why?
|
| Glossectomy | 1 | 2017 | 1 | 0.520 |
Why?
|
| Facial Recognition | 1 | 2017 | 35 | 0.510 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2016 | 265 | 0.510 |
Why?
|
| Patient Positioning | 1 | 2017 | 70 | 0.500 |
Why?
|
| Phenotype | 9 | 2022 | 3155 | 0.500 |
Why?
|
| Smartphone | 1 | 2017 | 106 | 0.490 |
Why?
|
| Posture | 1 | 2017 | 197 | 0.480 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 4 | 2021 | 153 | 0.480 |
Why?
|
| Virtual Reality | 1 | 2017 | 82 | 0.470 |
Why?
|
| Biomarkers, Tumor | 4 | 2021 | 1321 | 0.460 |
Why?
|
| MAP Kinase Signaling System | 4 | 2016 | 307 | 0.460 |
Why?
|
| Induction Chemotherapy | 1 | 2016 | 88 | 0.460 |
Why?
|
| Bone Marrow | 2 | 2018 | 306 | 0.450 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2023 | 992 | 0.440 |
Why?
|
| Head and Neck Neoplasms | 4 | 2017 | 561 | 0.430 |
Why?
|
| Simulation Training | 1 | 2017 | 135 | 0.430 |
Why?
|
| Models, Theoretical | 1 | 2018 | 558 | 0.420 |
Why?
|
| Physical Therapy Modalities | 1 | 2017 | 336 | 0.410 |
Why?
|
| T-Lymphocytes | 3 | 2024 | 1996 | 0.410 |
Why?
|
| Neoplastic Stem Cells | 3 | 2015 | 409 | 0.400 |
Why?
|
| Myeloid Cells | 1 | 2014 | 147 | 0.390 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2017 | 1443 | 0.390 |
Why?
|
| HLA-DR Antigens | 3 | 2021 | 220 | 0.390 |
Why?
|
| Lymphoma, B-Cell | 4 | 2017 | 140 | 0.370 |
Why?
|
| Oxidation-Reduction | 2 | 2015 | 1067 | 0.360 |
Why?
|
| Cell Line, Tumor | 10 | 2026 | 3542 | 0.360 |
Why?
|
| Metabolomics | 3 | 2024 | 732 | 0.350 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 981 | 0.350 |
Why?
|
| Endoscopy | 1 | 2014 | 317 | 0.350 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2025 | 919 | 0.340 |
Why?
|
| B-Lymphocyte Subsets | 2 | 2015 | 76 | 0.340 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2012 | 641 | 0.340 |
Why?
|
| Lateral Ventricles | 2 | 2023 | 32 | 0.330 |
Why?
|
| Antineoplastic Agents | 4 | 2022 | 2214 | 0.330 |
Why?
|
| Software | 4 | 2023 | 680 | 0.330 |
Why?
|
| Macrolides | 2 | 2024 | 67 | 0.320 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2023 | 409 | 0.320 |
Why?
|
| Databases as Topic | 1 | 2010 | 71 | 0.320 |
Why?
|
| Internet | 3 | 2015 | 689 | 0.310 |
Why?
|
| Lymphocyte Subsets | 1 | 2010 | 77 | 0.310 |
Why?
|
| Free Tissue Flaps | 2 | 2026 | 54 | 0.310 |
Why?
|
| Maxillofacial Prosthesis | 1 | 2009 | 1 | 0.300 |
Why?
|
| Maxillary Neoplasms | 1 | 2009 | 8 | 0.300 |
Why?
|
| Phosphoproteins | 3 | 2016 | 337 | 0.300 |
Why?
|
| Maxilla | 1 | 2009 | 36 | 0.300 |
Why?
|
| Gene Expression | 4 | 2016 | 1476 | 0.290 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2006 | 51 | 0.290 |
Why?
|
| Lymphatic Metastasis | 2 | 2026 | 331 | 0.290 |
Why?
|
| Publishing | 1 | 2010 | 114 | 0.290 |
Why?
|
| Lymphocytes | 2 | 2023 | 376 | 0.280 |
Why?
|
| Oximes | 2 | 2018 | 26 | 0.280 |
Why?
|
| Palatine Tonsil | 4 | 2018 | 54 | 0.280 |
Why?
|
| Anemia, Aplastic | 2 | 2020 | 42 | 0.270 |
Why?
|
| Aged | 17 | 2026 | 26153 | 0.270 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2014 | 337 | 0.270 |
Why?
|
| Pyrimidinones | 2 | 2018 | 125 | 0.260 |
Why?
|
| STAT1 Transcription Factor | 3 | 2022 | 66 | 0.260 |
Why?
|
| Leukemia | 2 | 2021 | 246 | 0.260 |
Why?
|
| Imidazoles | 2 | 2018 | 247 | 0.250 |
Why?
|
| Female | 30 | 2026 | 78844 | 0.250 |
Why?
|
| Middle Aged | 18 | 2026 | 36215 | 0.250 |
Why?
|
| Cell Communication | 2 | 2024 | 328 | 0.250 |
Why?
|
| Pyridones | 2 | 2018 | 209 | 0.240 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2006 | 56 | 0.240 |
Why?
|
| Theranostic Nanomedicine | 1 | 2026 | 15 | 0.240 |
Why?
|
| Porphyrins | 1 | 2026 | 16 | 0.240 |
Why?
|
| Cells, Cultured | 8 | 2021 | 4148 | 0.240 |
Why?
|
| Carcinogenesis | 2 | 2019 | 228 | 0.240 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2026 | 17 | 0.240 |
Why?
|
| DNA Damage | 3 | 2023 | 437 | 0.230 |
Why?
|
| Animals | 21 | 2026 | 38030 | 0.230 |
Why?
|
| Tyrosine | 1 | 2006 | 217 | 0.230 |
Why?
|
| Adult | 16 | 2026 | 40777 | 0.230 |
Why?
|
| Thyroidectomy | 1 | 2026 | 92 | 0.230 |
Why?
|
| Watchful Waiting | 1 | 2026 | 90 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2006 | 239 | 0.220 |
Why?
|
| Male | 25 | 2026 | 72842 | 0.220 |
Why?
|
| Multimodal Imaging | 1 | 2026 | 129 | 0.220 |
Why?
|
| Forkhead Transcription Factors | 2 | 2024 | 207 | 0.220 |
Why?
|
| Filipin | 1 | 2024 | 4 | 0.220 |
Why?
|
| Actinobacteria | 1 | 2024 | 15 | 0.220 |
Why?
|
| Young Adult | 8 | 2021 | 14218 | 0.210 |
Why?
|
| Tumor Cells, Cultured | 5 | 2020 | 886 | 0.210 |
Why?
|
| Fluorescence | 3 | 2019 | 159 | 0.210 |
Why?
|
| Structure-Activity Relationship | 1 | 2025 | 563 | 0.210 |
Why?
|
| Molecular Structure | 1 | 2025 | 486 | 0.200 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2021 | 699 | 0.200 |
Why?
|
| Cell Line | 3 | 2021 | 2823 | 0.200 |
Why?
|
| Apoptosis | 4 | 2020 | 2440 | 0.200 |
Why?
|
| Heterozygote | 1 | 2024 | 313 | 0.190 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2021 | 1140 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2006 | 534 | 0.190 |
Why?
|
| Pilot Projects | 3 | 2020 | 1891 | 0.190 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 2664 | 0.190 |
Why?
|
| Treatment Outcome | 8 | 2026 | 11772 | 0.180 |
Why?
|
| Cytokines | 4 | 2022 | 2067 | 0.180 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2022 | 29 | 0.180 |
Why?
|
| Small Molecule Libraries | 1 | 2023 | 111 | 0.180 |
Why?
|
| HMGB1 Protein | 1 | 2022 | 51 | 0.180 |
Why?
|
| CD57 Antigens | 1 | 2021 | 18 | 0.180 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2022 | 17 | 0.180 |
Why?
|
| Immunoglobulin G | 2 | 2022 | 892 | 0.180 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 137 | 0.180 |
Why?
|
| Thyroid Neoplasms | 1 | 2026 | 350 | 0.170 |
Why?
|
| Leukocyte Common Antigens | 3 | 2016 | 87 | 0.170 |
Why?
|
| STAT5 Transcription Factor | 4 | 2021 | 50 | 0.170 |
Why?
|
| Interleukin-2 | 2 | 2020 | 440 | 0.170 |
Why?
|
| Immunity | 1 | 2022 | 140 | 0.170 |
Why?
|
| Microscopy | 1 | 2023 | 147 | 0.170 |
Why?
|
| Myositis | 1 | 2022 | 57 | 0.170 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2026 | 497 | 0.170 |
Why?
|
| CD4 Antigens | 1 | 2021 | 137 | 0.170 |
Why?
|
| Extracellular Vesicles | 1 | 2024 | 171 | 0.170 |
Why?
|
| Mutation | 5 | 2024 | 4075 | 0.170 |
Why?
|
| Glutaminase | 1 | 2021 | 11 | 0.170 |
Why?
|
| Lipids | 1 | 2026 | 707 | 0.170 |
Why?
|
| Rhinovirus | 1 | 2021 | 60 | 0.170 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2021 | 48 | 0.160 |
Why?
|
| Cytomegalovirus | 1 | 2021 | 168 | 0.160 |
Why?
|
| Histones | 2 | 2023 | 666 | 0.160 |
Why?
|
| Containment of Biohazards | 1 | 2020 | 23 | 0.160 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 3413 | 0.160 |
Why?
|
| Prognosis | 5 | 2022 | 4316 | 0.160 |
Why?
|
| CD28 Antigens | 1 | 2020 | 59 | 0.160 |
Why?
|
| Fas Ligand Protein | 1 | 2020 | 61 | 0.160 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2022 | 288 | 0.160 |
Why?
|
| Nephritis | 1 | 2020 | 22 | 0.160 |
Why?
|
| Tomography, Optical | 1 | 2019 | 2 | 0.150 |
Why?
|
| Nanoparticles | 1 | 2026 | 517 | 0.150 |
Why?
|
| Hydrogen Peroxide | 2 | 2015 | 335 | 0.150 |
Why?
|
| Graft vs Host Disease | 2 | 2021 | 279 | 0.150 |
Why?
|
| Cytomegalovirus Infections | 1 | 2021 | 206 | 0.150 |
Why?
|
| Automation | 1 | 2020 | 104 | 0.150 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2019 | 32 | 0.150 |
Why?
|
| Mice | 9 | 2026 | 18329 | 0.150 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 244 | 0.150 |
Why?
|
| Equipment Design | 2 | 2019 | 525 | 0.150 |
Why?
|
| Lymphocyte Activation | 2 | 2021 | 1132 | 0.150 |
Why?
|
| Lung | 3 | 2025 | 4106 | 0.150 |
Why?
|
| Quality of Life | 2 | 2026 | 3204 | 0.150 |
Why?
|
| Tomography | 1 | 2019 | 45 | 0.150 |
Why?
|
| Adenoids | 1 | 2018 | 12 | 0.140 |
Why?
|
| Dexamethasone | 1 | 2021 | 365 | 0.140 |
Why?
|
| Cell Separation | 2 | 2017 | 305 | 0.140 |
Why?
|
| Tuberous Sclerosis | 1 | 2019 | 56 | 0.140 |
Why?
|
| Antibodies, Neoplasm | 1 | 2018 | 34 | 0.140 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2018 | 70 | 0.140 |
Why?
|
| Disease Progression | 4 | 2016 | 2864 | 0.140 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 138 | 0.140 |
Why?
|
| RNA, Viral | 1 | 2022 | 692 | 0.140 |
Why?
|
| Astrocytoma | 1 | 2019 | 130 | 0.140 |
Why?
|
| Neoplasm Proteins | 2 | 2016 | 441 | 0.130 |
Why?
|
| Benign Paroxysmal Positional Vertigo | 1 | 2017 | 8 | 0.130 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 674 | 0.130 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 230 | 0.130 |
Why?
|
| Sensitivity and Specificity | 2 | 2022 | 1997 | 0.130 |
Why?
|
| Biomarkers | 5 | 2022 | 4295 | 0.130 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2017 | 49 | 0.130 |
Why?
|
| Analgesics, Opioid | 1 | 2026 | 1149 | 0.130 |
Why?
|
| Facial Neoplasms | 1 | 2017 | 19 | 0.130 |
Why?
|
| Neural Stem Cells | 1 | 2019 | 168 | 0.130 |
Why?
|
| Proteins | 2 | 2019 | 1023 | 0.130 |
Why?
|
| Immunoglobulin M | 3 | 2022 | 265 | 0.130 |
Why?
|
| Hemangiosarcoma | 1 | 2017 | 25 | 0.120 |
Why?
|
| Scalp | 1 | 2017 | 38 | 0.120 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2016 | 36 | 0.120 |
Why?
|
| Jurkat Cells | 1 | 2016 | 115 | 0.120 |
Why?
|
| Receptors, Immunologic | 1 | 2017 | 208 | 0.120 |
Why?
|
| Immunomodulation | 1 | 2017 | 99 | 0.120 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2016 | 2 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 168 | 0.120 |
Why?
|
| Antigens, CD | 2 | 2016 | 558 | 0.120 |
Why?
|
| NF-kappa B | 2 | 2019 | 666 | 0.120 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 198 | 0.120 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 76 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2023 | 925 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 838 | 0.120 |
Why?
|
| Cryopreservation | 1 | 2017 | 113 | 0.120 |
Why?
|
| Neutrophils | 1 | 2022 | 1124 | 0.120 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 413 | 0.120 |
Why?
|
| Flavin-Adenine Dinucleotide | 1 | 2015 | 15 | 0.120 |
Why?
|
| Genes, MHC Class II | 1 | 2016 | 76 | 0.120 |
Why?
|
| NADP | 1 | 2015 | 52 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2016 | 5423 | 0.120 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2015 | 10 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 2 | 2016 | 1505 | 0.110 |
Why?
|
| Cetuximab | 1 | 2015 | 111 | 0.110 |
Why?
|
| Electromagnetic Fields | 1 | 2015 | 37 | 0.110 |
Why?
|
| Sepsis | 1 | 2022 | 664 | 0.110 |
Why?
|
| Workload | 1 | 2017 | 168 | 0.110 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2016 | 122 | 0.110 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2015 | 70 | 0.110 |
Why?
|
| Immune System | 1 | 2016 | 180 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 506 | 0.110 |
Why?
|
| Cell Differentiation | 3 | 2021 | 2046 | 0.110 |
Why?
|
| Cause of Death | 1 | 2017 | 470 | 0.110 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2015 | 117 | 0.110 |
Why?
|
| Antigen-Presenting Cells | 1 | 2015 | 159 | 0.110 |
Why?
|
| Precision Medicine | 1 | 2019 | 459 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2014 | 38 | 0.100 |
Why?
|
| Bronchoscopy | 1 | 2015 | 227 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2017 | 673 | 0.100 |
Why?
|
| Information Dissemination | 2 | 2020 | 224 | 0.100 |
Why?
|
| Oncogenes | 1 | 2014 | 118 | 0.100 |
Why?
|
| Histone Acetyltransferases | 1 | 2014 | 57 | 0.100 |
Why?
|
| Cisplatin | 1 | 2015 | 345 | 0.100 |
Why?
|
| Task Performance and Analysis | 1 | 2014 | 198 | 0.100 |
Why?
|
| Enzyme Activation | 2 | 2015 | 762 | 0.100 |
Why?
|
| Syk Kinase | 2 | 2016 | 19 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2026 | 8057 | 0.090 |
Why?
|
| DNA, Neoplasm | 1 | 2013 | 158 | 0.090 |
Why?
|
| Clonal Evolution | 1 | 2013 | 47 | 0.090 |
Why?
|
| Tongue Neoplasms | 1 | 2012 | 25 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2016 | 135 | 0.090 |
Why?
|
| Hypertension, Pulmonary | 1 | 2023 | 1957 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2017 | 1374 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2016 | 171 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2012 | 222 | 0.080 |
Why?
|
| Lymph Node Excision | 1 | 2012 | 173 | 0.080 |
Why?
|
| Cluster Analysis | 3 | 2020 | 500 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 1217 | 0.080 |
Why?
|
| Herpesvirus 4, Human | 2 | 2004 | 172 | 0.080 |
Why?
|
| CD79 Antigens | 2 | 2022 | 16 | 0.080 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2010 | 66 | 0.080 |
Why?
|
| Models, Immunological | 1 | 2010 | 99 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 8333 | 0.080 |
Why?
|
| Extracellular Space | 1 | 2010 | 117 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 187 | 0.080 |
Why?
|
| Transcription Factors | 2 | 2016 | 1734 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 849 | 0.080 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2009 | 23 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 5 | 2015 | 1041 | 0.070 |
Why?
|
| DNA, Viral | 2 | 2004 | 356 | 0.070 |
Why?
|
| Gene Expression Profiling | 3 | 2017 | 1767 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2016 | 431 | 0.070 |
Why?
|
| Epithelial Cells | 1 | 2015 | 1131 | 0.070 |
Why?
|
| Calibration | 2 | 2019 | 152 | 0.070 |
Why?
|
| Lymphocyte Depletion | 1 | 2009 | 132 | 0.070 |
Why?
|
| Asthma | 1 | 2021 | 1797 | 0.070 |
Why?
|
| Transplantation, Homologous | 2 | 2021 | 418 | 0.070 |
Why?
|
| Leukemia, Myelomonocytic, Juvenile | 1 | 2008 | 4 | 0.070 |
Why?
|
| Lymph Nodes | 2 | 2026 | 503 | 0.070 |
Why?
|
| Glycolysis | 2 | 2021 | 340 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2017 | 1243 | 0.070 |
Why?
|
| Myeloproliferative Disorders | 1 | 2008 | 21 | 0.070 |
Why?
|
| Phantoms, Imaging | 2 | 2019 | 159 | 0.070 |
Why?
|
| Probability | 1 | 2009 | 307 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2026 | 6066 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 866 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2026 | 17291 | 0.070 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 196 | 0.070 |
Why?
|
| Disease | 1 | 2009 | 96 | 0.070 |
Why?
|
| Osteotomy | 1 | 2009 | 128 | 0.070 |
Why?
|
| Cell Proliferation | 4 | 2021 | 2507 | 0.070 |
Why?
|
| Prosthesis Implantation | 1 | 2009 | 154 | 0.070 |
Why?
|
| Lymphoma | 1 | 2009 | 237 | 0.070 |
Why?
|
| Positron-Emission Tomography | 2 | 2026 | 343 | 0.060 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 462 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2009 | 260 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2023 | 779 | 0.060 |
Why?
|
| Bayes Theorem | 1 | 2009 | 420 | 0.060 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2006 | 110 | 0.060 |
Why?
|
| RNA-Binding Proteins | 1 | 2010 | 447 | 0.060 |
Why?
|
| Copper Radioisotopes | 1 | 2026 | 4 | 0.060 |
Why?
|
| Rats, Nude | 1 | 2026 | 25 | 0.060 |
Why?
|
| Peptide Mapping | 1 | 2006 | 62 | 0.060 |
Why?
|
| Time Factors | 3 | 2015 | 7123 | 0.060 |
Why?
|
| Celecoxib | 1 | 2026 | 42 | 0.060 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2026 | 19 | 0.060 |
Why?
|
| Amines | 1 | 2026 | 40 | 0.060 |
Why?
|
| Autoantibodies | 2 | 2025 | 1509 | 0.060 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 2188 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2025 | 2930 | 0.060 |
Why?
|
| Chemokine CXCL13 | 1 | 2025 | 15 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2026 | 161 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2012 | 1149 | 0.060 |
Why?
|
| Protein Isoforms | 1 | 2006 | 397 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2022 | 1508 | 0.050 |
Why?
|
| Adolescent | 3 | 2021 | 22529 | 0.050 |
Why?
|
| Secondary Metabolism | 1 | 2024 | 7 | 0.050 |
Why?
|
| Adaptation, Physiological | 1 | 2009 | 560 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2017 | 418 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2009 | 709 | 0.050 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2004 | 21 | 0.050 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2026 | 128 | 0.050 |
Why?
|
| Carcinogens, Environmental | 1 | 2004 | 14 | 0.050 |
Why?
|
| Mitochondria | 2 | 2020 | 992 | 0.050 |
Why?
|
| Haploinsufficiency | 1 | 2024 | 54 | 0.050 |
Why?
|
| Lymphopenia | 1 | 2024 | 62 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2010 | 686 | 0.050 |
Why?
|
| Analgesics | 1 | 2026 | 231 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2769 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2023 | 1716 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 716 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 365 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2022 | 3623 | 0.050 |
Why?
|
| Pain Measurement | 1 | 2026 | 561 | 0.050 |
Why?
|
| ras Proteins | 1 | 2004 | 150 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 456 | 0.050 |
Why?
|
| Acetaminophen | 1 | 2026 | 267 | 0.050 |
Why?
|
| Thymus Gland | 1 | 2024 | 312 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2012 | 3747 | 0.050 |
Why?
|
| Lipid Bilayers | 1 | 2024 | 103 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2026 | 4560 | 0.050 |
Why?
|
| Kinetics | 1 | 2006 | 1567 | 0.050 |
Why?
|
| Epoprostenol | 1 | 2023 | 132 | 0.050 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2023 | 196 | 0.050 |
Why?
|
| Benzamides | 1 | 2023 | 226 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1547 | 0.050 |
Why?
|
| Calreticulin | 1 | 2022 | 22 | 0.050 |
Why?
|
| Mevalonic Acid | 1 | 2002 | 12 | 0.050 |
Why?
|
| DNA Fingerprinting | 1 | 2002 | 28 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2004 | 231 | 0.050 |
Why?
|
| Mammals | 1 | 2024 | 286 | 0.050 |
Why?
|
| Lovastatin | 1 | 2002 | 37 | 0.050 |
Why?
|
| Gain of Function Mutation | 1 | 2022 | 35 | 0.050 |
Why?
|
| Buthionine Sulfoximine | 1 | 2002 | 9 | 0.050 |
Why?
|
| Pain Management | 1 | 2026 | 410 | 0.040 |
Why?
|
| Cell Count | 1 | 2022 | 319 | 0.040 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2023 | 218 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2004 | 396 | 0.040 |
Why?
|
| Nomograms | 1 | 2022 | 59 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2024 | 741 | 0.040 |
Why?
|
| Receptors, IgG | 1 | 2022 | 77 | 0.040 |
Why?
|
| Janus Kinase 1 | 1 | 2021 | 26 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 2382 | 0.040 |
Why?
|
| Alternaria | 1 | 2021 | 9 | 0.040 |
Why?
|
| Calgranulin B | 1 | 2021 | 10 | 0.040 |
Why?
|
| Pyroglyphidae | 1 | 2021 | 18 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 624 | 0.040 |
Why?
|
| Cell Death | 1 | 2022 | 382 | 0.040 |
Why?
|
| Listeriosis | 1 | 2021 | 63 | 0.040 |
Why?
|
| Tretinoin | 1 | 2021 | 125 | 0.040 |
Why?
|
| Glutamine | 1 | 2021 | 109 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2021 | 172 | 0.040 |
Why?
|
| Immune System Diseases | 1 | 2020 | 37 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2002 | 749 | 0.040 |
Why?
|
| Interleukin-7 | 1 | 2020 | 66 | 0.040 |
Why?
|
| Computer Simulation | 2 | 2015 | 1003 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 219 | 0.040 |
Why?
|
| Glutathione | 1 | 2002 | 370 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 354 | 0.040 |
Why?
|
| Th2 Cells | 1 | 2021 | 175 | 0.040 |
Why?
|
| Listeria monocytogenes | 1 | 2021 | 102 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2021 | 101 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 209 | 0.040 |
Why?
|
| Inventions | 1 | 2019 | 19 | 0.040 |
Why?
|
| Intraoperative Period | 1 | 2019 | 69 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2022 | 500 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2004 | 1480 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2023 | 588 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2015 | 934 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2020 | 369 | 0.040 |
Why?
|
| Linear Models | 1 | 2022 | 845 | 0.040 |
Why?
|
| Finite Element Analysis | 1 | 2019 | 67 | 0.040 |
Why?
|
| Thyroid Nuclear Factor 1 | 1 | 2019 | 16 | 0.040 |
Why?
|
| Pyridines | 1 | 2023 | 609 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 1471 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2002 | 611 | 0.040 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2002 | 268 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 5983 | 0.040 |
Why?
|
| Software Validation | 1 | 2018 | 9 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 613 | 0.030 |
Why?
|
| Rabbits | 1 | 2019 | 652 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2021 | 420 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2021 | 638 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2002 | 443 | 0.030 |
Why?
|
| Cell Extracts | 1 | 2018 | 19 | 0.030 |
Why?
|
| Streptomyces | 1 | 2018 | 9 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2022 | 776 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 133 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2020 | 385 | 0.030 |
Why?
|
| Salivary Glands | 1 | 1998 | 36 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2018 | 147 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 266 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2015 | 1490 | 0.030 |
Why?
|
| Pharynx | 1 | 1998 | 59 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2017 | 104 | 0.030 |
Why?
|
| Mouth Mucosa | 1 | 1998 | 85 | 0.030 |
Why?
|
| Rats | 1 | 2026 | 5584 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2009 | 5904 | 0.030 |
Why?
|
| Recurrence | 2 | 2013 | 1138 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 344 | 0.030 |
Why?
|
| Carrier State | 1 | 1998 | 78 | 0.030 |
Why?
|
| Ontario | 1 | 2017 | 90 | 0.030 |
Why?
|
| Tumor Escape | 1 | 2017 | 49 | 0.030 |
Why?
|
| Phospholipase C gamma | 1 | 2016 | 28 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2017 | 48 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2016 | 33 | 0.030 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2016 | 11 | 0.030 |
Why?
|
| Receptors, CCR4 | 1 | 2016 | 24 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2017 | 79 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2016 | 66 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 477 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2026 | 3904 | 0.030 |
Why?
|
| Protein Binding | 2 | 2014 | 2238 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2016 | 92 | 0.030 |
Why?
|
| fas Receptor | 1 | 2016 | 91 | 0.030 |
Why?
|
| Lanthanoid Series Elements | 1 | 2015 | 2 | 0.030 |
Why?
|
| A549 Cells | 1 | 2016 | 75 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2018 | 450 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 264 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2016 | 153 | 0.030 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2015 | 63 | 0.030 |
Why?
|
| Pleura | 1 | 2015 | 28 | 0.030 |
Why?
|
| Indocyanine Green | 1 | 2015 | 42 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 583 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 767 | 0.030 |
Why?
|
| Database Management Systems | 1 | 2015 | 51 | 0.030 |
Why?
|
| Stem Cells | 1 | 2019 | 628 | 0.030 |
Why?
|
| CREB-Binding Protein | 1 | 2015 | 34 | 0.030 |
Why?
|
| Glucose | 1 | 2020 | 1048 | 0.030 |
Why?
|
| Biological Transport | 1 | 2016 | 424 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2014 | 34 | 0.030 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2014 | 28 | 0.030 |
Why?
|
| Injections | 1 | 2015 | 199 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2015 | 254 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 969 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 1061 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2010 | 1179 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 440 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 325 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2017 | 1300 | 0.030 |
Why?
|
| Metabolome | 1 | 2018 | 388 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 2953 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2017 | 6013 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1266 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 1963 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2020 | 717 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2014 | 74 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1327 | 0.020 |
Why?
|
| Bronchi | 1 | 2015 | 263 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 333 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2015 | 364 | 0.020 |
Why?
|
| Histiocytes | 1 | 2013 | 7 | 0.020 |
Why?
|
| Mutation Rate | 1 | 2013 | 33 | 0.020 |
Why?
|
| E-Selectin | 1 | 2013 | 61 | 0.020 |
Why?
|
| RNA Interference | 1 | 2014 | 475 | 0.020 |
Why?
|
| Clone Cells | 1 | 2013 | 263 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2024 | 6447 | 0.020 |
Why?
|
| Neck Dissection | 1 | 2012 | 17 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2018 | 1808 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2013 | 207 | 0.020 |
Why?
|
| Exome | 1 | 2013 | 227 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2013 | 487 | 0.020 |
Why?
|
| Child | 4 | 2019 | 22707 | 0.020 |
Why?
|
| Interleukins | 1 | 2013 | 248 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2597 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2013 | 309 | 0.020 |
Why?
|
| Genotype | 1 | 2016 | 1852 | 0.020 |
Why?
|
| Chromatin | 1 | 2015 | 553 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2021 | 2341 | 0.020 |
Why?
|
| Genome, Human | 1 | 2013 | 420 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2010 | 149 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2010 | 376 | 0.020 |
Why?
|
| Graft Survival | 1 | 2012 | 518 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2013 | 530 | 0.020 |
Why?
|
| Immunization, Passive | 1 | 2009 | 90 | 0.020 |
Why?
|
| U937 Cells | 1 | 2009 | 28 | 0.020 |
Why?
|
| Reoperation | 1 | 2012 | 633 | 0.020 |
Why?
|
| Janus Kinase 2 | 1 | 2008 | 29 | 0.020 |
Why?
|
| Graft Rejection | 1 | 2012 | 521 | 0.020 |
Why?
|
| Registries | 1 | 2017 | 2406 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2016 | 2803 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 161 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 2090 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 368 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2019 | 11853 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2009 | 1261 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2009 | 480 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 2028 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 2004 | 25 | 0.010 |
Why?
|
| Activating Transcription Factors | 1 | 2002 | 3 | 0.010 |
Why?
|
| Diazepam Binding Inhibitor | 1 | 2002 | 2 | 0.010 |
Why?
|
| Phalloidine | 1 | 2002 | 3 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Synthase | 1 | 2002 | 3 | 0.010 |
Why?
|
| Polyisoprenyl Phosphates | 1 | 2002 | 4 | 0.010 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2002 | 13 | 0.010 |
Why?
|
| Sterols | 1 | 2002 | 20 | 0.010 |
Why?
|
| Coenzyme A Ligases | 1 | 2002 | 15 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 2002 | 73 | 0.010 |
Why?
|
| Subtraction Technique | 1 | 2002 | 26 | 0.010 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2002 | 37 | 0.010 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2002 | 56 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2009 | 1164 | 0.010 |
Why?
|
| Dithiothreitol | 1 | 2002 | 19 | 0.010 |
Why?
|
| Cytochrome c Group | 1 | 2002 | 43 | 0.010 |
Why?
|
| Luciferases | 1 | 2002 | 153 | 0.010 |
Why?
|
| COS Cells | 1 | 2002 | 177 | 0.010 |
Why?
|
| Antigens | 1 | 2004 | 348 | 0.010 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2002 | 76 | 0.010 |
Why?
|
| Transcription Factor RelA | 1 | 2002 | 86 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2002 | 277 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2002 | 106 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 1764 | 0.010 |
Why?
|
| Cytosol | 1 | 2002 | 213 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2002 | 278 | 0.010 |
Why?
|
| United States | 1 | 2018 | 16098 | 0.010 |
Why?
|
| Blood Proteins | 1 | 2002 | 239 | 0.010 |
Why?
|
| Protein Transport | 1 | 2002 | 442 | 0.010 |
Why?
|
| Cholesterol | 1 | 2002 | 408 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2004 | 1111 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2002 | 666 | 0.010 |
Why?
|
| Cell Survival | 1 | 2002 | 1100 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2004 | 2121 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2002 | 598 | 0.010 |
Why?
|
| Parotid Gland | 1 | 1998 | 17 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2002 | 1246 | 0.010 |
Why?
|